Loading…
Long-acting somatostatin analogues decrease blood transfusion requirements in patients with refractory gastrointestinal bleeding associated with angiodysplasia
Summary Background Gastrointestinal angiodysplasias (GIADs) may be the cause of recurrent bleeding, despite endoscopic treatment. Aim To evaluate the effect of long‐acting somatostatin analogues on blood transfusion requirements, in patients with refractory bleeding due to GIADs. Methods Consecutive...
Saved in:
| Published in: | Alimentary pharmacology & therapeutics 2012-09, Vol.36 (6), p.587-593 |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c3930-da8ad1cd3139ad1fa9a52cd3c285385ef6b3c1831dec02735b251f0b3b3e7b1d3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c3930-da8ad1cd3139ad1fa9a52cd3c285385ef6b3c1831dec02735b251f0b3b3e7b1d3 |
| container_end_page | 593 |
| container_issue | 6 |
| container_start_page | 587 |
| container_title | Alimentary pharmacology & therapeutics |
| container_volume | 36 |
| creator | Bon, C. Aparicio, T. Vincent, M. Mavros, M. Bejou, B. Raynaud, J.-J. Zampeli, E. Airinei, G. Sautereau, D. Benamouzig, R. Michopoulos, S. |
| description | Summary
Background
Gastrointestinal angiodysplasias (GIADs) may be the cause of recurrent bleeding, despite endoscopic treatment.
Aim
To evaluate the effect of long‐acting somatostatin analogues on blood transfusion requirements, in patients with refractory bleeding due to GIADs.
Methods
Consecutive patients with recurrent bleeding from GIADs were enrolled. They received somatostatin analogue treatment for at least 6 months. The efficacy was evaluated in terms of blood transfusions, frequency of bleeding episodes and haemoglobin level during 6 months of treatment (Period During) compared to a 6‐months' period before treatment (Period Before).
Results
Fifteen patients were enrolled from 2007 to 2010. The median duration of somatostatin analogue treatment was 12 months (range: 6–36). The number of transfusions significantly decreased in Period During compared with Period Before [median number: 2 (0–14) vs. 10 (6–24); P |
| doi_str_mv | 10.1111/apt.12000 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1035101283</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1035101283</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3930-da8ad1cd3139ad1fa9a52cd3c285385ef6b3c1831dec02735b251f0b3b3e7b1d3</originalsourceid><addsrcrecordid>eNp1kU1v1DAQhiMEokvhwB9AuSDBIa0_6iR7rCooiOVD7CKO1sR2giGJU4-jsr-Gv8q02ZYTvtgjP-87emey7DlnJ5zOKUzphAvG2INsxWWpCsFk-TBbMVGuC1FzeZQ9QfxJQFkx8Tg7EqKW_KxUq-zPJoxdASb5scsxDJACJqAqhxH60M0Oc-tMdIAub_oQbJ4ijNjO6MOYR3c1--gGNybMSTSR9PZ97dMP-m0jWYe4zzvAFIMfk0Myh568nLM3TQExGA_J2UUEY-eD3ePUA3p4mj1qoUf37HAfZ9_evtldvCs2ny_fX5xvCiPXkhUWarDcWMnlmh4trEEJKo2olayVa8tGGk6hKQsTlVSNULxljWykqxpu5XH2avGdYrii0EkPHo3rexhdmFFzJhVnnOZG6OsFNTEgUkY9RT9A3BOkb_ahaR_6dh_EvjjYzs3g7D15twACXh4AQAM9zWs0Hv9xpRRnqiyJO124a9-7_f876vMvu7vWxaLwmNzvewXEX7qsZKX090-Xevf1w0e23Qq9lX8BPFS2lA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1035101283</pqid></control><display><type>article</type><title>Long-acting somatostatin analogues decrease blood transfusion requirements in patients with refractory gastrointestinal bleeding associated with angiodysplasia</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Bon, C. ; Aparicio, T. ; Vincent, M. ; Mavros, M. ; Bejou, B. ; Raynaud, J.-J. ; Zampeli, E. ; Airinei, G. ; Sautereau, D. ; Benamouzig, R. ; Michopoulos, S.</creator><creatorcontrib>Bon, C. ; Aparicio, T. ; Vincent, M. ; Mavros, M. ; Bejou, B. ; Raynaud, J.-J. ; Zampeli, E. ; Airinei, G. ; Sautereau, D. ; Benamouzig, R. ; Michopoulos, S.</creatorcontrib><description>Summary
Background
Gastrointestinal angiodysplasias (GIADs) may be the cause of recurrent bleeding, despite endoscopic treatment.
Aim
To evaluate the effect of long‐acting somatostatin analogues on blood transfusion requirements, in patients with refractory bleeding due to GIADs.
Methods
Consecutive patients with recurrent bleeding from GIADs were enrolled. They received somatostatin analogue treatment for at least 6 months. The efficacy was evaluated in terms of blood transfusions, frequency of bleeding episodes and haemoglobin level during 6 months of treatment (Period During) compared to a 6‐months' period before treatment (Period Before).
Results
Fifteen patients were enrolled from 2007 to 2010. The median duration of somatostatin analogue treatment was 12 months (range: 6–36). The number of transfusions significantly decreased in Period During compared with Period Before [median number: 2 (0–14) vs. 10 (6–24); P < 0.001]. The percentage of patients who experienced a bleeding event was lower during somatostatin analogues treatment (20% vs. 73%; P = 0.01). The mean haemoglobin level was significantly higher when somatostatin analogues were offered [median: 10 g/dL (9–13) vs. 7 (5–8.5); P < 0.001]. None of the patients discontinued treatment due to side effects.
Conclusions
Long‐acting somatostatin analogues treatment decreased transfusion needs in patients with refractory bleeding from gastrointestinal angiodysplasias. Bleeding episodes were limited and haemoglobin improved during treatment. Long‐acting somatostatin analogues may represent an option for the management of patients with chronic bleeding due to gastrointestinal angiodysplasias.</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1111/apt.12000</identifier><identifier>PMID: 22831465</identifier><language>eng</language><publisher>Oxford: Blackwell Publishing Ltd</publisher><subject>Aged ; Aged, 80 and over ; Angiodysplasia - complications ; Angiodysplasia - drug therapy ; Biological and medical sciences ; Blood Transfusion ; Colonoscopy ; Digestive system ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; Gastrointestinal Hemorrhage - etiology ; Gastrointestinal Hemorrhage - prevention & control ; Gastroscopy ; Hormones - therapeutic use ; Humans ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Randomized Controlled Trials as Topic ; Somatostatin - analogs & derivatives ; Somatostatin - therapeutic use ; Time Factors ; Tomography, X-Ray Computed ; Treatment Outcome</subject><ispartof>Alimentary pharmacology & therapeutics, 2012-09, Vol.36 (6), p.587-593</ispartof><rights>2012 Blackwell Publishing Ltd</rights><rights>2015 INIST-CNRS</rights><rights>2012 Blackwell Publishing Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3930-da8ad1cd3139ad1fa9a52cd3c285385ef6b3c1831dec02735b251f0b3b3e7b1d3</citedby><cites>FETCH-LOGICAL-c3930-da8ad1cd3139ad1fa9a52cd3c285385ef6b3c1831dec02735b251f0b3b3e7b1d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26324566$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22831465$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bon, C.</creatorcontrib><creatorcontrib>Aparicio, T.</creatorcontrib><creatorcontrib>Vincent, M.</creatorcontrib><creatorcontrib>Mavros, M.</creatorcontrib><creatorcontrib>Bejou, B.</creatorcontrib><creatorcontrib>Raynaud, J.-J.</creatorcontrib><creatorcontrib>Zampeli, E.</creatorcontrib><creatorcontrib>Airinei, G.</creatorcontrib><creatorcontrib>Sautereau, D.</creatorcontrib><creatorcontrib>Benamouzig, R.</creatorcontrib><creatorcontrib>Michopoulos, S.</creatorcontrib><title>Long-acting somatostatin analogues decrease blood transfusion requirements in patients with refractory gastrointestinal bleeding associated with angiodysplasia</title><title>Alimentary pharmacology & therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Summary
Background
Gastrointestinal angiodysplasias (GIADs) may be the cause of recurrent bleeding, despite endoscopic treatment.
Aim
To evaluate the effect of long‐acting somatostatin analogues on blood transfusion requirements, in patients with refractory bleeding due to GIADs.
Methods
Consecutive patients with recurrent bleeding from GIADs were enrolled. They received somatostatin analogue treatment for at least 6 months. The efficacy was evaluated in terms of blood transfusions, frequency of bleeding episodes and haemoglobin level during 6 months of treatment (Period During) compared to a 6‐months' period before treatment (Period Before).
Results
Fifteen patients were enrolled from 2007 to 2010. The median duration of somatostatin analogue treatment was 12 months (range: 6–36). The number of transfusions significantly decreased in Period During compared with Period Before [median number: 2 (0–14) vs. 10 (6–24); P < 0.001]. The percentage of patients who experienced a bleeding event was lower during somatostatin analogues treatment (20% vs. 73%; P = 0.01). The mean haemoglobin level was significantly higher when somatostatin analogues were offered [median: 10 g/dL (9–13) vs. 7 (5–8.5); P < 0.001]. None of the patients discontinued treatment due to side effects.
Conclusions
Long‐acting somatostatin analogues treatment decreased transfusion needs in patients with refractory bleeding from gastrointestinal angiodysplasias. Bleeding episodes were limited and haemoglobin improved during treatment. Long‐acting somatostatin analogues may represent an option for the management of patients with chronic bleeding due to gastrointestinal angiodysplasias.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Angiodysplasia - complications</subject><subject>Angiodysplasia - drug therapy</subject><subject>Biological and medical sciences</subject><subject>Blood Transfusion</subject><subject>Colonoscopy</subject><subject>Digestive system</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Gastrointestinal Hemorrhage - etiology</subject><subject>Gastrointestinal Hemorrhage - prevention & control</subject><subject>Gastroscopy</subject><subject>Hormones - therapeutic use</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Somatostatin - analogs & derivatives</subject><subject>Somatostatin - therapeutic use</subject><subject>Time Factors</subject><subject>Tomography, X-Ray Computed</subject><subject>Treatment Outcome</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNp1kU1v1DAQhiMEokvhwB9AuSDBIa0_6iR7rCooiOVD7CKO1sR2giGJU4-jsr-Gv8q02ZYTvtgjP-87emey7DlnJ5zOKUzphAvG2INsxWWpCsFk-TBbMVGuC1FzeZQ9QfxJQFkx8Tg7EqKW_KxUq-zPJoxdASb5scsxDJACJqAqhxH60M0Oc-tMdIAub_oQbJ4ijNjO6MOYR3c1--gGNybMSTSR9PZ97dMP-m0jWYe4zzvAFIMfk0Myh568nLM3TQExGA_J2UUEY-eD3ePUA3p4mj1qoUf37HAfZ9_evtldvCs2ny_fX5xvCiPXkhUWarDcWMnlmh4trEEJKo2olayVa8tGGk6hKQsTlVSNULxljWykqxpu5XH2avGdYrii0EkPHo3rexhdmFFzJhVnnOZG6OsFNTEgUkY9RT9A3BOkb_ahaR_6dh_EvjjYzs3g7D15twACXh4AQAM9zWs0Hv9xpRRnqiyJO124a9-7_f876vMvu7vWxaLwmNzvewXEX7qsZKX090-Xevf1w0e23Qq9lX8BPFS2lA</recordid><startdate>201209</startdate><enddate>201209</enddate><creator>Bon, C.</creator><creator>Aparicio, T.</creator><creator>Vincent, M.</creator><creator>Mavros, M.</creator><creator>Bejou, B.</creator><creator>Raynaud, J.-J.</creator><creator>Zampeli, E.</creator><creator>Airinei, G.</creator><creator>Sautereau, D.</creator><creator>Benamouzig, R.</creator><creator>Michopoulos, S.</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201209</creationdate><title>Long-acting somatostatin analogues decrease blood transfusion requirements in patients with refractory gastrointestinal bleeding associated with angiodysplasia</title><author>Bon, C. ; Aparicio, T. ; Vincent, M. ; Mavros, M. ; Bejou, B. ; Raynaud, J.-J. ; Zampeli, E. ; Airinei, G. ; Sautereau, D. ; Benamouzig, R. ; Michopoulos, S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3930-da8ad1cd3139ad1fa9a52cd3c285385ef6b3c1831dec02735b251f0b3b3e7b1d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Angiodysplasia - complications</topic><topic>Angiodysplasia - drug therapy</topic><topic>Biological and medical sciences</topic><topic>Blood Transfusion</topic><topic>Colonoscopy</topic><topic>Digestive system</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Gastrointestinal Hemorrhage - etiology</topic><topic>Gastrointestinal Hemorrhage - prevention & control</topic><topic>Gastroscopy</topic><topic>Hormones - therapeutic use</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Somatostatin - analogs & derivatives</topic><topic>Somatostatin - therapeutic use</topic><topic>Time Factors</topic><topic>Tomography, X-Ray Computed</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bon, C.</creatorcontrib><creatorcontrib>Aparicio, T.</creatorcontrib><creatorcontrib>Vincent, M.</creatorcontrib><creatorcontrib>Mavros, M.</creatorcontrib><creatorcontrib>Bejou, B.</creatorcontrib><creatorcontrib>Raynaud, J.-J.</creatorcontrib><creatorcontrib>Zampeli, E.</creatorcontrib><creatorcontrib>Airinei, G.</creatorcontrib><creatorcontrib>Sautereau, D.</creatorcontrib><creatorcontrib>Benamouzig, R.</creatorcontrib><creatorcontrib>Michopoulos, S.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Alimentary pharmacology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bon, C.</au><au>Aparicio, T.</au><au>Vincent, M.</au><au>Mavros, M.</au><au>Bejou, B.</au><au>Raynaud, J.-J.</au><au>Zampeli, E.</au><au>Airinei, G.</au><au>Sautereau, D.</au><au>Benamouzig, R.</au><au>Michopoulos, S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-acting somatostatin analogues decrease blood transfusion requirements in patients with refractory gastrointestinal bleeding associated with angiodysplasia</atitle><jtitle>Alimentary pharmacology & therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>2012-09</date><risdate>2012</risdate><volume>36</volume><issue>6</issue><spage>587</spage><epage>593</epage><pages>587-593</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract>Summary
Background
Gastrointestinal angiodysplasias (GIADs) may be the cause of recurrent bleeding, despite endoscopic treatment.
Aim
To evaluate the effect of long‐acting somatostatin analogues on blood transfusion requirements, in patients with refractory bleeding due to GIADs.
Methods
Consecutive patients with recurrent bleeding from GIADs were enrolled. They received somatostatin analogue treatment for at least 6 months. The efficacy was evaluated in terms of blood transfusions, frequency of bleeding episodes and haemoglobin level during 6 months of treatment (Period During) compared to a 6‐months' period before treatment (Period Before).
Results
Fifteen patients were enrolled from 2007 to 2010. The median duration of somatostatin analogue treatment was 12 months (range: 6–36). The number of transfusions significantly decreased in Period During compared with Period Before [median number: 2 (0–14) vs. 10 (6–24); P < 0.001]. The percentage of patients who experienced a bleeding event was lower during somatostatin analogues treatment (20% vs. 73%; P = 0.01). The mean haemoglobin level was significantly higher when somatostatin analogues were offered [median: 10 g/dL (9–13) vs. 7 (5–8.5); P < 0.001]. None of the patients discontinued treatment due to side effects.
Conclusions
Long‐acting somatostatin analogues treatment decreased transfusion needs in patients with refractory bleeding from gastrointestinal angiodysplasias. Bleeding episodes were limited and haemoglobin improved during treatment. Long‐acting somatostatin analogues may represent an option for the management of patients with chronic bleeding due to gastrointestinal angiodysplasias.</abstract><cop>Oxford</cop><pub>Blackwell Publishing Ltd</pub><pmid>22831465</pmid><doi>10.1111/apt.12000</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-2813 |
| ispartof | Alimentary pharmacology & therapeutics, 2012-09, Vol.36 (6), p.587-593 |
| issn | 0269-2813 1365-2036 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1035101283 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | Aged Aged, 80 and over Angiodysplasia - complications Angiodysplasia - drug therapy Biological and medical sciences Blood Transfusion Colonoscopy Digestive system Female Gastroenterology. Liver. Pancreas. Abdomen Gastrointestinal Hemorrhage - etiology Gastrointestinal Hemorrhage - prevention & control Gastroscopy Hormones - therapeutic use Humans Male Medical sciences Middle Aged Pharmacology. Drug treatments Randomized Controlled Trials as Topic Somatostatin - analogs & derivatives Somatostatin - therapeutic use Time Factors Tomography, X-Ray Computed Treatment Outcome |
| title | Long-acting somatostatin analogues decrease blood transfusion requirements in patients with refractory gastrointestinal bleeding associated with angiodysplasia |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T20%3A30%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-acting%20somatostatin%20analogues%20decrease%20blood%20transfusion%20requirements%20in%20patients%20with%20refractory%20gastrointestinal%20bleeding%20associated%20with%20angiodysplasia&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=Bon,%20C.&rft.date=2012-09&rft.volume=36&rft.issue=6&rft.spage=587&rft.epage=593&rft.pages=587-593&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1111/apt.12000&rft_dat=%3Cproquest_cross%3E1035101283%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3930-da8ad1cd3139ad1fa9a52cd3c285385ef6b3c1831dec02735b251f0b3b3e7b1d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1035101283&rft_id=info:pmid/22831465&rfr_iscdi=true |